Indeed, this protein was found to be involved in BC growth and metastasis and promote epithelial-to-mesenchymal transition in TNBC [45–47], suggesting that PRAME could serve as a prognostic biomarker and/or therapeutic target in TNBC. This evidence concerns the gene PRAME and breast cancer.